Unit and Chair of Rheumatology, University and A.O.U. of Cagliari, Cagliari, Italy, Cardiology Department, Avicenne Hospital, Bobigny and Cochin Hospital, Paris XIII University, APHP, Paris, France, Department of Rheumatology, Hospital for Special Surgery, New York, NY, Stanford University School of Medicine, Stanford, VA Palo Alto Health Care System, Palo Alto, CA, USA, Rheumatology Unit, Royal Adelaide Hospital, North Terrace, Adelaide, SA, Australia, Health Science Center at Houston, University of Texas, Houston, TX, USA, St Vincent's Hospital, University of Melbourne, Fitzroy, Melbourne, VIC, Australia, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Mexico City, Mexico, Scleroderma Program, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, Boston University School of Medicine, Boston, MA, USA, Rheumatology Division, Department of Internal Medicine, University of Florence, Florence, Italy, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland and Rheumatology A Department, Cochin Hospital, APHP, Paris Descartes University, Paris, France.
Unit and Chair of Rheumatology, University and A.O.U. of Cagliari, Cagliari, Italy, Cardiology Department, Avicenne Hospital, Bobigny and Cochin Hospital, Paris XIII University, APHP, Paris, France, Department of Rheumatology, Hospital for Special Surgery, New York, NY, Stanford University School of Medicine, Stanford, VA Palo Alto Health Care System, Palo Alto, CA, USA, Rheumatology Unit, Royal Adelaide Hospital, North Terrace, Adelaide, SA, Australia, Health Science Center at Houston, University of Texas, Houston, TX, USA, St Vincent's Hospital, University of Melbourne, Fitzroy, Melbourne, VIC, Australia, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Mexico City, Mexico, Scleroderma Program, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, Boston University School of Medicine, Boston, MA, USA, Rheumatology Division, Department of Internal Medicine, University of Florence, Florence, Italy, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland and Rheumatology A Department, Cochin Hospital, APHP, Paris Descartes University, Paris, France.Unit and Chair of Rheumatology, University and A.O.U. of Cagliari, Cagliari, Italy, Cardiology Department, Avicenne Hospital, Bobigny and Cochin Hospital, Paris XIII University, APHP, Paris, France, Department of Rheumatology, Hospital for Special Surgery, New York, NY, Stanford University School of Medicine, Stanford, VA Palo Alto Health Care System, Palo Alto, CA, USA, Rheumatology Unit, Royal Adelaide Hospital, North Terrace, Adelaide, SA, Australia, Health Science Center at Houston, University of Texas, Houston, TX, USA, St Vincent's Hospital, University of Melbourne, Fitzroy, Melbourne, VIC, Australia, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Mexico City, Mexico, Scleroderma Program, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, Boston University School of Medicine, Boston, MA, USA, Rheumatology Division
Rheumatology (Oxford). 2014 Jul;53(7):1172-7. doi: 10.1093/rheumatology/ket377. Epub 2013 Nov 15.
Signs and symptoms of arrhythmias or conduction defects are frequently reported in patients with SSc. These rhythm disorders may have several origins (i.e., related to primary heart involvement, pericardial disease, valvular regurgitation or pulmonary arterial hypertension) and may negatively affect the overall prognosis of these patients. It is therefore important to identify patients at high risk for cardiac arrhythmias with a complete cardiological evaluation and to identify the underlying heart disease, including SSc-related myocardial involvement. In addition, some therapeutic options in SSc patients may differ from those recommended in other populations.
硬皮病患者常出现心律失常或传导缺陷的症状和体征。这些节律障碍可能有多种起源(即与原发性心脏受累、心包疾病、瓣膜反流或肺动脉高压有关),并可能对这些患者的总体预后产生负面影响。因此,通过全面的心脏评估识别发生心律失常风险较高的患者,并识别潜在的心脏病,包括硬皮病相关的心肌受累非常重要。此外,硬皮病患者的一些治疗选择可能与其他人群推荐的治疗选择不同。